PPD
Clinical Research Headquarters
929 North Front Street
Wilmington
North Carolina
28401
United States
Tel: 910-251-0081
Website: https://www.ppd.com/
About PPD
PPD is part of Thermo Fisher Scientific. As the world’s leader in serving science, our professionals develop critical solutions—and build rewarding careers. We offer services and products that help customers around the globe in laboratories and clinics, on production lines and out in the field.
We’re a driving force in the research, healthcare, industrial and applied markets, generating more $35 billion in annual revenue. No other company can match our range of customer touch points—technologically, geographically or commercially. We help customers in finding cures for cancer, protecting the environment, bringing medicines to market, making sure our food is safe and moving forward with thousands of important projects that improve millions of lives.
Stock Symbol: TMO
Stock Exchange: NYSE
Find PPD on social media:
Find PPD Careers on social media:
We All Have Our Why | PPD
444 articles about PPD
-
PPD Announces First Quarter 2021 Earnings Conference Call
4/7/2021
PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, will host a conference call on Wednesday, April 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its first quarter 2021 financial results.
-
PPD Named a Leader in Digital Clinical Trial Solutions by ISG
3/17/2021
PPD Named a Leader in Digital Clinical Trial Solutions by ISG Recognized for comprehensive strengths in the design, deployment of decentralized solutions
-
PPD Lights Up Headquarters Downtown for 2021 Rare Disease Day
2/26/2021
Rare Disease Day takes place on the last day of February because it is a month known for having a “rare” number of days.
-
PPD to Present at Barclays Global Healthcare Conference
2/24/2021
PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, will present virtually at the Barclays Global Healthcare Conference. David Simmons, chairman and CEO, and Chris Scully, CFO, are scheduled to participate in a fireside chat on Tuesday, March 9, 2021, at 3:35 p.m. (U.S. Eastern Time).
-
PPD Reports Fourth Quarter and Full Year 2020 Results
2/23/2021
PPD, Inc., a leading global contract research organization, reported its financial results for the fourth quarter and full year ended December 31, 2020.
-
PPD Awarded US Army Study to Help Develop Post-Traumatic Stress Disorder Drugs
2/18/2021
PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, has been awarded Defense Health Agency funds to support a five-year Research Project Award (RPA) to develop and execute an adaptive platform clinical research trial of drug interventions to treat post-traumatic stress disorder (PTSD).
-
PPD Honored for Employee Development Programs that Deliver Results for Customers
2/17/2021
PPD, Inc. has been recognized for the 10th consecutive year as one of the leading U.S. businesses for employee learning and development.
-
AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections
2/9/2021
AzurRx BioPharma, Inc. (NASDAQ: AZRX ), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into an agreement with PPD, Inc. (NASDAQ: PPD ), a leading global contract research organization (CRO), for its planned Phase 2 clinic trial
-
PPD Announces Fourth Quarter and Full-Year 2020 Earnings Conference Call
2/3/2021
PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, will host a conference call on Wednesday, Feb. 24, 2021, at 9 a.m. (U.S. Eastern Time) to discuss its fourth quarter and full-year 2020 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging on to the investors section of PPD’s website at https://investors.ppd.com .
-
PPD to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/4/2021
PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference. David Simmons, chairman and CEO, and Chris Scully, CFO, are scheduled to present on Monday, Jan. 11, 2021, at 2:50 p.m. (U.S. Eastern Time). A live and archived webcast of the presentation, along with accompanying slides, will be accessible for up to 30 days through
-
PPD Recognized as a Best Place to Work in Greater China
12/7/2020
PPD, Inc. (Nasdaq: PPD ) has been named one of the Best Workplaces in Greater China™ by Great Place to Work ® , a global authority on high-trust, high-performance workplace cultures that provides executive advisory and culture consulting services to businesses, nonprofits and government agencies. The honor builds on the announcement by PPD to adopt a new Mandarin company name in China to reflect its continuing growth
-
PPD Named Clinical Research Company of the Year
11/2/2020
PPD, Inc. (Nasdaq: PPD ), was named the Clinical Research Company of the Year for winning multiple awards at the PharmaTimes Clinical Researcher of the Year competitions. In addition to PPD winning the highest honor at the PharmaTimes International Clinical Researcher of the Year 2020 virtual awards ceremony, individual PPD clinical researchers won gold and bronze in both the Clinical Research Associate (CRA) and
-
PPD Announces Third Quarter 2020 Earnings Conference Call
10/12/2020
PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, will host a conference call on Wednesday, Oct. 28, 2020, at 9 a.m. (U.S. Eastern Time) to discuss its third quarter 2020 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging onto the investors section of PPD’s website at https://investors.ppd.com . An archive copy of the webcast w
-
PPD Achieves ISO/IEC 27001:2013 Certification for Information Security Management
9/30/2020
PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, has achieved the internationally recognized information security certification ISO/IEC 27001:2013, demonstrating the company’s commitment to ensuring the protection of its customers’ data. ISO/IEC 27001:2013 is an information security standard published by the International Organization for Standardization (ISO), the world’s largest develop
-
PPD Announces Pricing of Secondary Offering of Shares of Common Stock - Sep 17, 2020
9/17/2020
PPD, Inc., a leading global contract research organization, announced the pricing of an underwritten public offering by certain stockholders of the Company, including stockholders affiliated with Hellman & Friedman LLC and The Carlyle Group Inc., of 38,000,000 shares of the Company’s common stock at a price to the public of $32.25 per share.
-
PPD Named a Top 50 Employer in Bulgaria
9/17/2020
PPD, Inc. (Nasdaq: PPD ), has been recognized as a top employer in Bulgaria, adding to the global contract research organization’s growing list of accolades as an employer of choice around the world. PPD was recognized as a top 50 desirable employer in Bulgaria, according to the second annual Employer of Choice Survey organized by the employer brand and business consulting agency To The Top. The organization sel
-
PPD Announces Secondary Offering of Shares of Common Stock - Sep 14, 2020
9/14/2020
PPD, Inc. announced that certain stockholders of the Company, including stockholders affiliated with Hellman & Friedman LLC and The Carlyle Group Inc., have commenced an underwritten public offering of 38,000,000 shares of the Company’s common stock pursuant to a registration statement filed with the Securities and Exchange Commission.
-
PPD Updates Third Quarter 2020 Financial Guidance
9/14/2020
PPD, Inc., a leading global contract research organization, updated its financial guidance for the third quarter ending September 30, 2020.
-
PPD Recognized for Excellence in Clinical Research Training
9/9/2020
PPD, Inc. (Nasdaq: PPD ) has earned recognition for its global employee learning and development program in the Brandon Hall Group Human Capital Management (HCM) Excellence in Learning Awards . PPD was recognized with the Brandon Hall Gold Award in two categories – “best use of blended learning” for its clinical foundation progra
-
PPD and Lupus Therapeutics Collaborate to Support Lupus Clinical Research
9/3/2020
PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, and Lupus Therapeutics (LT), an affiliate of the Lupus Research Alliance known for its lupus clinical trials expertise, have entered into a collaboration to expand and enhance lupus clinical research for PPD’s pharmaceutical and biotech customers. This press release features multimedia. View the full release here: https://www.businesswire.c